智通财经APP讯，今海医疗科技(02225)发布截至2024年12月31日止年度业绩，该集团期内取得收益5024.1万新加坡元，同比增加10.07%。
公告称，收益增加主要由于近年中国微创手术解决方案业务增长，使集团于该年度的收入增长。
来自微创手术解决方案及医疗产品和相关服务费的收益由2023财年的2040万新加坡元增加至2024财年的2590万新加坡元。增加主要由于中国的微创手术解决方案业务增长。
鉴于市场对微创手术解决方案、医疗产品及相关服务展现出的正面反馈，集团的收入大幅增长，集团将持续通过(a)加强其开发能力;(b)扩大其分销网络;(c) 开发新产品;及(d)促进资源整合，发展及提升其在日益激烈的市场竞争中的竞争力，从而巩固集团在医疗行业的地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.